Next Article in Journal
Oxidative DNA Damage and Carotid Intima Media Thickness as Predictors of Cardiovascular Disease in Prediabetic Subjects
Next Article in Special Issue
Using cAMP Sensors to Study Cardiac Nanodomains
Previous Article in Journal
Hyperglycemia Alters the Structure and Hemodynamics of the Developing Embryonic Heart
Previous Article in Special Issue
A-Kinase Anchoring Protein-Lbc: A Molecular Scaffold Involved in Cardiac Protection
Article Menu

Export Article

Open AccessReview
J. Cardiovasc. Dev. Dis. 2018, 5(1), 14; https://doi.org/10.3390/jcdd5010014

Roles of A-Kinase Anchoring Proteins and Phosphodiesterases in the Cardiovascular System

1
Max Delbrück Center for Molecular Medicine Berlin (MDC), Berlin 13125, Germany
2
DZHK (German Centre for Cardiovascular Research), partner site Berlin 13347, Germany
*
Author to whom correspondence should be addressed.
Received: 31 January 2018 / Revised: 16 February 2018 / Accepted: 18 February 2018 / Published: 20 February 2018
(This article belongs to the Special Issue Cyclic Nucleotide Signaling and the Cardiovascular System)
View Full-Text   |   Download PDF [1565 KB, uploaded 21 February 2018]   |  

Abstract

A-kinase anchoring proteins (AKAPs) and cyclic nucleotide phosphodiesterases (PDEs) are essential enzymes in the cyclic adenosine 3’-5’ monophosphate (cAMP) signaling cascade. They establish local cAMP pools by controlling the intensity, duration and compartmentalization of cyclic nucleotide-dependent signaling. Various members of the AKAP and PDE families are expressed in the cardiovascular system and direct important processes maintaining homeostatic functioning of the heart and vasculature, e.g., the endothelial barrier function and excitation-contraction coupling. Dysregulation of AKAP and PDE function is associated with pathophysiological conditions in the cardiovascular system including heart failure, hypertension and atherosclerosis. A number of diseases, including autosomal dominant hypertension with brachydactyly (HTNB) and type I long-QT syndrome (LQT1), result from mutations in genes encoding for distinct members of the two classes of enzymes. This review provides an overview over the AKAPs and PDEs relevant for cAMP compartmentalization in the heart and vasculature and discusses their pathophysiological role as well as highlights the potential benefits of targeting these proteins and their protein-protein interactions for the treatment of cardiovascular diseases. View Full-Text
Keywords: cAMP; compartmentalization; A-kinase anchoring proteins (AKAP); cyclic nucleotide phosphodiesterases (PDE); PDE inhibitors cAMP; compartmentalization; A-kinase anchoring proteins (AKAP); cyclic nucleotide phosphodiesterases (PDE); PDE inhibitors
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Ercu, M.; Klussmann, E. Roles of A-Kinase Anchoring Proteins and Phosphodiesterases in the Cardiovascular System. J. Cardiovasc. Dev. Dis. 2018, 5, 14.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
J. Cardiovasc. Dev. Dis. EISSN 2308-3425 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top